Dengue Vaccine Market to Reach US$ 2.62 Billion by 2033 at 14.8% CAGR; Asia-Pacific and Latin America Lead Growth | Key Players Sanofi, GSK, Takeda

The dengue vaccine market reached US$ 1.22 billion in 2024 and is expected to reach around US$ 2.62 billion by 2033, growing at a CAGR of about 14.8% during the forecast period 2025-2033. Market growth is driven by the rising global incidence of dengue, increasing public health initiatives to integrate vaccination into national programs, and the approval and adoption of next-generation vaccines, supporting broader immunization coverage and stronger market expansion.

North America held a significant market share due to strong preventive healthcare infrastructure, extensive research and vaccine development activities, and early adoption of dengue vaccines. Europe is witnessing growth supported by clinical trials and awareness campaigns, while Asia-Pacific and Latin America are expected to register the fastest growth, driven by high dengue prevalence, government vaccination programs, expanding immunization coverage, and rising healthcare investments in tropical and subtropical regions.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/dengue-vaccine-market?sai-v

The dengue vaccine market refers to the global industry focused on the development, production, and commercialization of vaccines aimed at preventing dengue virus infections.

Key Developments
✅ January 2026: In Asia-Pacific, expanded government immunization programs and public health initiatives increased adoption of dengue vaccines, with Takeda Pharmaceutical Company's TAK‐003 (QDENGA) leading regional rollout and uptake in endemic countries.

✅ January 2026: In Latin America, national vaccination campaigns intensified following updated WHO recommendations, supporting broader deployment of dengue vaccines from Takeda and other emerging developers to curb seasonal outbreaks.

✅ December 2025: In Southeast Asia, ongoing clinical studies and post‐market surveillance data reinforced long‐term safety and efficacy of live attenuated dengue vaccines, encouraging expanded use among children and young adults.

✅ December 2025: Globally, vaccine developers advanced next‐generation dengue vaccine candidates, including tetravalent subunit and DNA vaccine platforms, driven by research from Institut Pasteur, Takis Biotech, and Vaxess Technologies.

✅ November 2025: In India and neighboring endemic regions, partnerships between public health agencies and manufacturers streamlined cold chain logistics and expanded access to dengue immunization through community healthcare networks.

✅ October 2025: Worldwide, scientific collaboration forums and regional task forces shared efficacy, serotype‐specific protection, and safety data to inform optimal vaccine deployment strategies, supporting efforts led by WHO, Gavi, and PATH.

Mergers & Acquisitions

✅ January 2026: Takeda Pharmaceutical Company expanded its dengue vaccine portfolio through strategic investments and licensing agreements with regional vaccine developers to support local manufacturing and distribution.

✅ December 2025: In Europe, a global vaccine firm completed the acquisition of a dengue vaccine research platform specialist to augment early‐stage development capabilities and accelerate next‐generation candidate pipelines.

✅ November 2025: In Asia‐Pacific, a biotechnology contract research organization acquired dengue vaccine formulation technology from a regional innovator to support advanced clinical and manufacturing services.

Key Players
Sanofi | Panacea Biotec | Biological E. Limited | GlaxoSmithKline plc | Merck & Co. | Takeda Pharmaceutical Company Ltd | Vabiotec | Medigen Biologics | Others

Key Highlights
Sanofi holds 21% share, driven by its strong global vaccines portfolio, large-scale manufacturing capabilities, and continued innovation in infectious disease prevention.

GlaxoSmithKline plc holds 18% share, supported by leadership in vaccines, advanced adjuvant systems, and extensive global distribution networks.

Merck & Co. holds 15% share, leveraging robust vaccine R&D capabilities, strategic collaborations, and a diversified immunization portfolio.

Takeda Pharmaceutical Company Ltd holds 12% share, driven by specialty vaccine development, international partnerships, and focus on rare and emerging diseases.

Panacea Biotec holds 9% share, supported by cost-effective vaccine manufacturing, domestic market leadership, and expanding export footprint.

Biological E. Limited holds 8% share, leveraging expertise in large-scale biologics production and government contracts for immunization programs.

Vabiotec holds 6% share, driven by niche vaccine development, regional market focus, and strategic collaborations.

Medigen Biologics holds 5% share, supported by recombinant vaccine technologies, biologics innovation, and regional partnerships.

Others collectively hold 6% share, comprising emerging biotech firms and regional vaccine manufacturers advancing novel immunization solutions.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=dengue-vaccine-market?sai-v

Market Drivers
- Rising global prevalence of dengue infections, particularly in tropical and subtropical regions, increasing demand for effective vaccines.

- Growing public health initiatives and government immunization programs targeting mosquito‐borne diseases.

- Advancements in vaccine research and development leading to safer and more effective dengue vaccine candidates.

- Increasing healthcare spending and expanding access to preventive vaccines in both developed and emerging markets.

- Supportive regulatory frameworks and accelerated approval pathways for novel dengue vaccines.

Industry Developments
- Expansion of clinical trials evaluating next‐generation dengue vaccine candidates with improved efficacy across all four serotypes.

- Strategic partnerships between pharmaceutical companies, biotech firms, and public health organizations to accelerate vaccine development and distribution.

- Development of thermostable and single‐dose vaccine formulations to enhance accessibility in low‐resource settings.

- Increasing investment in vaccine manufacturing capacity and supply chain enhancements to support large‐scale immunization efforts.

- Growing focus on combination vaccines and multivalent platforms targeting multiple mosquito‐borne diseases.

Regional Insights
North America - 35% share: "Driven by heightened surveillance, increasing travel‐related dengue cases, and strong public health infrastructure supporting vaccine adoption."

Europe - 20% share: "Supported by research collaborations, regulatory engagement in vaccine development, and increased focus on mosquito‐borne disease preparedness."

Asia Pacific - 30% share: "Fueled by high dengue endemicity, expanding immunization programs, government support, and growing vaccine awareness."

Latin America - 10% share: "Driven by significant disease burden, national dengue vaccination campaigns, and expanding healthcare access."

Middle East & Africa - 5% share: "Supported by emerging public health initiatives, increasing disease surveillance, and expanding vaccine distribution efforts."

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/dengue-vaccine-market?sai-v

Key Segments

By Product Type
CYD-TDV, a tetravalent dengue vaccine, dominates the market as a preventive solution against dengue infections. Its adoption is driven by increasing prevalence of dengue fever in endemic regions, government immunization programs, and rising awareness about disease prevention.

By Distribution Channel
Hospital pharmacies represent the largest distribution channel, supported by vaccine administration in clinical and public health settings. Retail pharmacies and drug stores hold a significant share, driven by ease of access for routine vaccination programs. Online pharmacies are witnessing steady growth due to digital adoption and home delivery convenience. Other channels include government immunization centers, public health clinics, and private vaccination programs, contributing to overall market reach.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.